首页 / 院系成果 / 成果详情页

Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial 期刊论文

编号：

5DCE7EAA5DDDB330D6EBD45AF39CC26B
作者：

Huang, Dong(黄东)#^[1]Ma, Yuanji^[1];Wu, Hongxian^[1];Zhong, Xin^[1];Gao, Wei^[1];Zhou, Jun^[2];Qian, Juying(钱菊英)^[1]Ge, Junbo(葛均波)*^[1]
语种：

英文
期刊：

CARDIOVASCULAR DIAGNOSIS AND THERAPY ISSN：2223-3652 2022 年 ; 2022 JUN 1
收录：
关键词：

Myocardial infarction reteplase percutaneous coronary intervention (PCI) infarct size
摘要：

Background: Thrombus embolization and microvascular obstruction during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is commonly detected, which causes inadequate myocardial perfusion and elevated infarct size. An approach with low-dose intracoronary fibrinolytic treatment for reducing distal embolization and improving myocardial reperfusion in high-risk STEMI cases remains controversial. Methods: The RECOVER II study represents a multicenter, randomized, double-blind, parallel-group trial assessing low-dose adjunctive intracoronary reteplase during primary PCI in individuals with large anterior myocardial infarction and thrombus determined by angiography. The trial will enroll 306 cases who present within 12 h following STEMI for proximal or mid left anterior descending artery occlusion undergoing primary PCI. Cases will be randomized to receive a bolus intracoronary reteplase at 9 mg or 18 mg vs. placebo. The drug will be delivered over 2 minutes proximal to culprit lesions with an intracoronary catheter early after wire-crossing and before thrombus aspiration or balloon dilation. Results: The primary outcome will be infarct size assessed by late gadolinium-enhanced magnetic resonance imaging (MRI) (% of left ventricular mass) on day 7 after enrollment. Secondary outcomes will include the amount of microvascular obstruction and myocardial salvage index examined via MRI on day 7, angiographic measures of reperfusion [Thrombolysis in Myocardial Infarction (TIMI) coronary flow grade, TIMI frames count and myocardial blush grade], incidence of complete ST-segment resolution at 2 hours after reperfusion, area under the curve for troponin T, and rates of major adverse cardiovascular events at 30 days. Conclusions: RECOVER II will determine whether the addition of low-dose intracoronary reteplase early after wire-crossing as an adjunct to reperfusion treatment reduces infarct size in individuals with large anterior myocardial infarction. Trial Registration: The trial was registered on ClinicalTrials.gov (NCT04571580).
推荐引用方式
GB/T 7714：

Huang Dong,Ma Yuanji,Wu Hongxian, et al. Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial [J].CARDIOVASCULAR DIAGNOSIS AND THERAPY,2022.
APA：

Huang Dong,Ma Yuanji,Wu Hongxian,Zhong Xin,&Ge Junbo.(2022).Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial .CARDIOVASCULAR DIAGNOSIS AND THERAPY.
MLA：

Huang Dong, et al. "Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial" .CARDIOVASCULAR DIAGNOSIS AND THERAPY(2022).
入库时间：

2023/12/2 0:00:00
更新时间：

2023/12/2 0:00:00

浏览次数：18  下载次数：0

分享到：

浏览次数：18

下载次数：0

打印次数：0